Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Corvus Pharmaceuticals Inc

Current price
2.23 USD +0.03 USD (+1.36%)
Last closed 2.16 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 136 361 840 USD
Yield for 12 month -7.85 %
21.11.2021 - 28.11.2021

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California. Address: 863 Mitten Road, Burlingame, CA, United States, 94010

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

7.83 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

+246 000 USD

Current Year

-151 000 USD

Last Year

-367 000 USD

Current Quarter

-23 000 USD

Last Quarter

+218 000 USD

Key Figures CRVS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -22 947 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -29.33 %
PEG Ratio
Return On Equity TTM -60.46 %
Wall Street Target Price 7.83 USD
Revenue TTM
Book Value 0.68 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -0.51 USD
Diluted Eps TTM -0.51 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CRVS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CRVS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CRVS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -2.1179
Price Book MRQ 1.9395

Financials CRVS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CRVS

For 52 weeks

1.05 USD 2.58 USD
50 Day MA 2.03 USD
Shares Short Prior Month 1 504 810
200 Day MA 1.82 USD
Short Ratio 7.96
Shares Short 1 430 669
Short Percent 2.84 %

Dynamics of changes in the value of assets



Detailed analytics


407.00 JPY Paris Miki Holdings Inc -0.01 (-0.25%)
Detailed analytics


0.55 EUR DURO FELGUE. INH. EO-05 -0.02 (-2.64%)
Detailed analytics


0.28 EUR BIOPORTO A/S B DK 1 +0 (+0%)
Detailed analytics


36.60 TRY Meditera Tibbi Malzeme Sanayi ve Ticaret AS -0.02 (-1.56%)
Detailed analytics